Bausch (BHC) Surges 11.7%: Is This an Indication of Further Gains?
Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels
Bausch + Lomb stock has rebounded since January, but still offers value, especially with potential takeover interest and a solid balance sheet. BLCO shares trade at a reasonable premium to forward earnings, with a current ratio of 1.66, providing flexibility despite recent unprofitability. Risks include potential failure of takeover, economic downturns, inflation, and majority ownership by BHC, which could affect independent operations.
Op-ed: Here's why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors
Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don't think like your typical corporate board, writes Ken Squire of 13D Monitor.
Bausch & Lomb reportedly exploring sale, shares rise
Bausch & Lomb stock surged on reports the American-Canadian eye health products firm is exploring a sale as it seeks to resolve issues related to its separation from its debt-laden parent company Bausch Health Cos Inc (NYSE:BHC). According to a Financial Times report citing people familiar with the matter, Bausch & Lomb is working with Goldman Sachs to gauge interest from potential buyers.
Bausch + Lomb's stock soars 18% on report company is considering selling itself
Eye-care company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported.
Here's Why Bausch Health (BHC) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older
LAVAL, QC / ACCESSWIRE / September 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the approval by Health Canada of PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1%, a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older.1 CABTREO is the first and only triple-combination topical treatment for acne approved by Health Canada with three mechanisms of action - an antibiotic, a retinoid and an antibacterial agent - to provide a safe and effective treatment.1 "The approval of CABTREO shows the continuing commitment of Bausch Health to bring innovative dermatology treatments to Canadians," said Amy Cairns, Vice-President, Commercial and General Manager, Canada, Bausch Health. "We are proud to offer this first triple-combination topical acne treatment to millions of Canadians who suffer from acne each year.
Bausch Health Solvency Remains A Concerns, Analyst Downgrades Stock
On Thursday, Bausch Health Companies BHC reported a second-quarter 2024 GAAP EPS of $0.03 compared to the consensus of $0.28.
Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales
Bausch Health's (BHC) second-quarter adjusted earnings meet estimates while sales top the same, fueled by growth in Xifaxan sales.
Bausch Health Companies (BHC) Q2 2024 Earnings Call Transcript
Bausch Health Companies (NYSE:BHC ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Thomas Appio - Chief Executive Officer John Barresi - Interim Chief Financial Officer Garen Sarafian - Investor Relations Conference Call Participants Glen Santangelo - Jefferies Mike Nedelcovych - TD Cowen Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Leszek Sulewski - Truist Securities David Amsellem - Piper Sandler Michael Freeman - Raymond James Operator Greetings! Welcome to the Bausch Health Second Quarter 2024 Earnings Call.
Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bausch Health (BHC) Beats Q2 Earnings and Revenue Estimates
Bausch Health (BHC) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.81 per share a year ago.
